Home » Newsletters » BioWorld Science

BioWorld Science

March 6, 2007

View Archived Issues

Antigenics updates pipeline progress

Recent GlaxoSmithKline patents report novel analgesic agents

Novel therapeutic option for thrombosis reported in recent Wyeth patent

Positive phase III results for rilonacept in cryopyrin-associated periodic syndromes

C1 inhibitor concentrate relieves skin swelling in hereditary angioedema

Preseasonal treatment increases grass allergen tablet efficacy

Bevacizumab active in pretreated ovarian cancer

Pfizer reports phase III data for maraviroc

Dermatrends and Teikoku Pharma to develop antipsychotic patch formulation

Sebivo approved in China for chronic hepatitis B

Aegis forms spin-out company Cedar Therapeutics

Samaritan completes acquisition of Metastatin Pharmaceuticals

Protox Therapeutics anticipates 2007 milestones

Argenta and Genentech expand drug discovery agreement

CRT and Fox Chase begin drug discovery collaboration in oncology

Gruenenthal licenses urinary incontinence product to KeyNeurotek

Extension study opens for MBP-8298 in secondary progressive MS

Novavax licenses VLP technology from U. of Massachusetts

TMC-278 meets 48-week endpoint in treatment-naive HIV patients

Bosentan meets endpoints in chronic thromboembolic pulmonary hypertension

PCSK9: a novel target for lowering LDL and preventing coronary heart disease

DPPI mediates neutrophil recruitment and inflammation in abdominal aortic aneurysms

Recent patents disclose novel agents for treating anxiety, depression, sleep disorders, etc.

Remicade receives new E.U. approval for dosing flexibilty in rheumatoid arthritis

U.S. first to approve Tekturna

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.